FDA Guidances On Lupus Drug Development Call For Superiority Trials

For development of drugs for either 1systemic lupus erythematosus or 2lupus nephritis, the gold standard study design is a randomized superiority trial, using either placebo or active control with the investigational therapy as an add-on to standard of care, according to a pair of final guidances released by FDA June 21